UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation

Journal for Immunotherapy of Cancer, 2016-11, Vol.4 (1), p.76-76, Article 76

2016

Link zum Volltext

Verfügbarkeit prüfen

Melanoma: a model for testing new agents in combination therapies

Journal of translational medicine, 2010-04, Vol.8 (1), p.38-38, Article 38

2010

Link zum Volltext

Verfügbarkeit prüfen

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Journal of clinical oncology, 2023-01, Vol.41 (2), p.186-197

2023

Link zum Volltext

Verfügbarkeit prüfen

Biology of advanced uveal melanoma and next steps for clinical therapeutics

Pigment cell and melanoma research, 2015-03, Vol.28 (2), p.135-147

2015

Link zum Volltext

Verfügbarkeit prüfen

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations

Journal for Immunotherapy of Cancer, 2016-11, Vol.4 (1), p.77-77, Article 77

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical Trial Design and Regulatory Issues for Therapeutic Cancer Vaccines

Cancer treatment and research, 2005, Vol.123, p.351-368

2005

Link zum Volltext

Verfügbarkeit prüfen

Clinical trials referral resource. Current clinical trials of thalidomide

Oncology (Williston Park, N.Y.), 2003-03, Vol.17 (3), p.369-380

2003

Link zum Volltext

Verfügbarkeit prüfen

Gallo's virus sequence

Nature (London), 1991-05, Vol.351 (6325), p.358-358

1991

Link zum Volltext

Verfügbarkeit prüfen

HTLV-III/LAV and the monocyte/macrophage

JAMA : the journal of the American Medical Association, 1986-11, Vol.256 (17), p.2390

1986

Link zum Volltext

Verfügbarkeit prüfen

Human retroviruses and human disease

Death studies, 1988-01, Vol.12 (5-6), p.381-397

1988

Link zum Volltext

Verfügbarkeit prüfen

Helper T-Cell Antigenic Site Identification in the Acquired Immunodeficiency Syndrome Virus gp120 Envelope Protein and Induction of Immunity in Mice to the Native Protein Using a 16-Residue Synthetic Peptide

Proceedings of the National Academy of Sciences - PNAS, 1987-06, Vol.84 (12), p.4249-4253

1987

Link zum Volltext

Verfügbarkeit prüfen

Antigen Conformation Determines Processing Requirements for T-Cell Activation

Proceedings of the National Academy of Sciences - PNAS, 1984-11, Vol.81 (21), p.6831-6835

1984

Link zum Volltext

Verfügbarkeit prüfen

Antigen Processing for Presentation to T Lymphocytes: Function, Mechanisms, and Implications for the T-Cell Repertoire

Immunological reviews, 1988-12, Vol.106 (1), p.5-31

1988

Link zum Volltext

Verfügbarkeit prüfen

Syndromes of toluene sniffing in adults

Annals of internal medicine, 1981-06, Vol.94 (6), p.758

1981

Link zum Volltext

Verfügbarkeit prüfen

Model for studying virus attachment. II. Binding of biotinylated human T cell leukemia virus type I to human blood mononuclear cells potential targets for human T cell leukemia virus type I infection

The Journal of immunology (1950), 1991-07, Vol.147 (1), p.102

1991

Link zum Volltext

Verfügbarkeit prüfen

The mononuclear phagocyte as antigen-presenting cell

Pediatric annals, 1987-05, Vol.16 (5), p.395

1987

Link zum Volltext

Verfügbarkeit prüfen

HTLV-III/LAV and the origin and pathogenesis of AIDS

International archives of allergy and applied immunology, 1987, Vol.82 (3-4), p.471

1987

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

The lancet oncology, 2022-02, Vol.23 (2), p.279-291

2022

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Clinical cancer research, 2021-05, Vol.27 (9), p.2470-2480

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11516-11516

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients

Journal of clinical oncology, 2005-06, Vol.23 (18), p.4089-4099

2005

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab, tremelimumab alone or in combination with low-dose or hypofractionated targeted radiotherapy in metastatic non-small cell lung cancer refractory to prior PD(L)-1 therapy: a multicentre, open-label, randomised, phase 2 trial

The lancet oncology, 2022-01, Vol.23 (2), p.279-291

2022

Link zum Volltext

Verfügbarkeit prüfen

Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Clinical cancer research, 2021-09, Vol.27 (17), p.4940-4940

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT163: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the small cell carcinoma of the ovary, hypercalcemic type cohort

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT163-CT163

2023

Link zum Volltext

Verfügbarkeit prüfen

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology

Journal of translational medicine, 2009-06, Vol.7 (1), p.45-45, Article 45

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(16)
Science & Technology
(15)
Life Sciences & Biomedicine
(14)
Oncology
(8)
Aids/hiv
(5)
Animals
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Biomarkers
(4)
Cancer
(4)
Clinical Trials As Topic
(4)
Immunology
(4)
Male
(4)
Treatment Outcome
(4)
Antigens
(3)
B7-H1 Antigen - Antagonists & Inhibitors
(3)
Biological And Medical Sciences
(3)
Cancer Therapies
(3)
Female
(3)
Health Aspects
(3)
Immunotherapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation

Melanoma: a model for testing new agents in combination therapies

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Biology of advanced uveal melanoma and next steps for clinical therapeutics

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations

Clinical Trial Design and Regulatory Issues for Therapeutic Cancer Vaccines

Clinical trials referral resource. Current clinical trials of thalidomide

Gallo's virus sequence

HTLV-III/LAV and the monocyte/macrophage

Human retroviruses and human disease

Helper T-Cell Antigenic Site Identification in the Acquired Immunodeficiency Syndrome Virus gp120 Envelope Protein and Induction of Immunity in Mice to the Native Protein Using a 16-Residue Synthetic Peptide

Antigen Conformation Determines Processing Requirements for T-Cell Activation

Antigen Processing for Presentation to T Lymphocytes: Function, Mechanisms, and Implications for the T-Cell Repertoire

Syndromes of toluene sniffing in adults

Model for studying virus attachment. II. Binding of biotinylated human T cell leukemia virus type I to human blood mononuclear cells potential targets for human T cell leukemia virus type I infection

The mononuclear phagocyte as antigen-presenting cell

HTLV-III/LAV and the origin and pathogenesis of AIDS

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27)

Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients

Durvalumab, tremelimumab alone or in combination with low-dose or hypofractionated targeted radiotherapy in metastatic non-small cell lung cancer refractory to prior PD(L)-1 therapy: a multicentre, open-label, randomised, phase 2 trial

Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

Abstract CT163: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the small cell carcinoma of the ovary, hypercalcemic type cohort

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology

Suchergebnisse filtern